Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2015-05-06 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-NAZAIRE (44600), Loire-Atlantique
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE SOREL : revenue, balance sheet and financial ratios
PHARMACIE SOREL is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-NAZAIRE (44600),
this company of category PME
shows in 2022 a revenue of 1.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE SOREL (SIREN 811290501)
Indicator
2024
2023
2022
2021
2020
2018
2017
2016
Revenue
N/C
N/C
1 592 460 €
N/C
N/C
N/C
N/C
N/C
Net income
121 919 €
126 531 €
124 961 €
124 469 €
139 805 €
140 982 €
147 311 €
140 176 €
EBITDA
N/C
N/C
166 706 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
7.8%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE SOREL generates positive net income of 122 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 140 k€ -> 122 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
121 919 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 28%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 72%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
28.154%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
71.629%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
Debt ratio
531.504
258.089
161.383
80.421
63.701
50.108
39.0
28.154
Financial autonomy
14.066
26.094
36.185
51.968
56.64
61.36
67.106
71.629
Repayment capacity
None
None
None
None
None
3.326
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
8.235%
None%
None%
Sector positioning
Debt ratio
28.152024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good-6 pts over 3 years
In 2024, the debt ratio of PHARMACIE SOREL (28.15) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
71.63%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+8 pts over 3 years
In 2024, the financial autonomy of PHARMACIE SOREL (71.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
3.33 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Good
In 2022, the repayment capacity of PHARMACIE SOREL (3.33) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 486.24. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
486.244
Liquidity indicators evolution PHARMACIE SOREL
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
Liquidity ratio
241.971
440.995
593.832
594.55
514.227
486.573
575.596
486.244
Interest coverage
None
None
None
None
None
2.994
None
None
Sector positioning
Liquidity ratio
486.242024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Excellent
In 2024, the liquidity ratio of PHARMACIE SOREL (486.24) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
2.99x2022
2022
Q1: 0.75x
Med: 2.51x
Q3: 5.16x
Good
In 2022, the interest coverage of PHARMACIE SOREL (3.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE SOREL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
87 442 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
18
0
0
Customer payment term (days)
140
151
159
84
95
6
0
0
Supplier payment term (days)
409
399
315
366
431
24
0
0
Positioning of PHARMACIE SOREL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE SOREL is estimated at
1 702 079 €
(range 1 185 301€ - 2 546 408€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1185k€1702k€2546k€
1 702 079 €Range: 1 185 301€ - 2 546 408€
NAF 5 année 2024
Valuation method used
Net Income Multiple
121 919 €
×
14.0x
=1 702 079 €
Range: 1 185 301€ - 2 546 408€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE SOREL with other companies in the same sector:
Yes, PHARMACIE SOREL generated a net profit of 122 k€ in 2024.
Where is the headquarters of PHARMACIE SOREL ?
The headquarters of PHARMACIE SOREL is located in SAINT-NAZAIRE (44600), in the department Loire-Atlantique.
Where to find the tax return of PHARMACIE SOREL ?
The tax return of PHARMACIE SOREL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE SOREL operate?
PHARMACIE SOREL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart